Immune functions of serum amyloid A

Critical Reviews in Immunology

Volumn 32, Issue 4, 2012, Pages 335-348

  Eklund, K K ^a   Niemi, K ^a   Kovanen, P T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Immune function; NLRP3 inflammasome; Serum amyloid A

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CLASS B SCAVENGER RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; INFLAMMASOME; INTERLEUKIN 1BETA; MEMBRANE PROTEIN; NRLP3 PROTEIN; SCAVENGER RECEPTOR; SERUM AMYLOID A; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; HUMAN; IMMUNITY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW;

EID: 84871283478     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v32.i4.40     Document Type: Review

References (103)

1. Benditt EP, Eriksen N. Chemical classes of amyloid substance. Am J Pathol. 1971;65:231-252.
2. Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest. 1972;51:2773-6.
3. Morrow JF, Stearman RS, Peltzman CG, Potter DA. Induction of hepatic synthesis of serum amyloid A protein and actin. Proc Natl Acad Sci U S A. 1981;78:4718-22.
4. Santiago P, Roig-López JL, Santiago C, García-Arrarás JE. Serum amyloid A protein in an echinoderm: its primary structure and expression during intestinal regeneration in the sea cucumber Holothuria glaberrima. J Exp Zool. 2000;288:335-44.
5. Hari-Dass R, Shah C, Meyer DJ. Raynes JG. Serum amyloid A protein binds to outer membrane protein A of Gram-negative bacteria. J Biol Chem. 2005;280:18562-7.
6. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease evidence from two distinct arteriosclerotic processes. Circulation. 1997;96:2914-9.
7. King V, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2011;22(4):302-7.
8. Dong Z, Wu T, Qin W, An C, Wang Z, Zhang M, Zhang Y, Zhang C, An F. Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein e-deficient mice. Mol Med. 2011;17:1357-64.
9. Sellar GC, Oghene K, Boyle S, Bickmore WA, Whitehead AS. Organization of the region encompassing the human serum amyloid A (SAA) gene family on chromosome 11p15.1. Genomics. 1994;23:492-5.
10. Sellar GC, Jordan SA, Bickmore WA, Fantes JA, van Heyningen V, Whitehead AS. The human serum amyloid A protein (SAA) superfamily gene cluster: mapping to chromosome 11p15.1 by physical and genetic linkage analysis. Genomics. 1994;19:221-7.
11. Kluve-Beckerman B, Drumm ML, Benson MD. Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol. 1991;10:651-61.
12. Sellar GC, Whitehead AS. Localization of four human serum amyloid A (SAA) protein superfamily genes to chromosome 11p: characterization of a fifth SAA-related gene sequence. Genomics. 1993;16:774-6.
13. Steel DM, Whitehead AS. The major acute-phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994;15:81-8.
14. Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, Lane WS, de Beer FC. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem. 1992;267:3862-7.
15. de Beer MC, Kindy MS, Lane WS, de Beer FC. Mouse serum amyloid A protein (SAA5) structure and expression. J Biol Chem. 1994;269:4661-4667.
16. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-23.
17. Uhlar CM, Burgess CJ, Sharp PM, Whitehead AS. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics. 1994;19:228-35.
18. Turnell W, Sarra R, Glover ID, Baum JO, Caspi D, Baltz ML, Pepys MB. Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites. Mol Biol Med.1986;3:387-407.
19. Pepys MB, Baltz M, Gomer K, Davies AJ, Doenhoff M. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature. 1979;278:259-61.
20. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity: a clue to serum amyloid A's principal function. Lab Invest. 1992;66:778-85.
21. Westermark GT, Engström U, Westermark P. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun. 1992;182:27-33.
22. Liang JS, Sipe JD. Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J Lipid Res. 1995;36:37-46.
23. Uhlar CM, Grehan S, Steel DM, Steinkasserer A, Whitehead AS. Use of the acute phase serum amyloid A2 (SAA2) gene promoter in the analysis of pro-and anti-inflammatory mediators: differential kinetics of SAA2 promoter induction by IL-1 beta and TNF-alpha compared to IL-6. J J Immunol Methods. 1997;203:123-30.
24. Yamada T, Wada A, Itoh Y, Itoh K. Serum amyloid A1 alleles and plasma concentrations of serum amyloid A. Amyloid. 1999;6:199-204.
25. Marhaug G, Sletten K, Husby G. Characterization of amyloid related protein SAA complexed with serum lipoproteins (apoSAA). Clin Exp Immunol. 1982;50:382-9.
26. Ogasawara K, Mashiba S, Wada Y, Sahara M, Uchida K, Aizawa T, Kodama T. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis. 2004;174:349-56.
27. Lewis KE, Kirk EA, McDonald TO, Wang S, Wight TN, O'Brien KD, Chait A. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation. 2004;110:540-5.
28. Subramanian S, Han CY, Chiba T, McMillen TS, Wang SA, Haw A 3rd, Kirk EA, O'Brien KD, Chait A. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28: 685-91.
29. King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, Tannock LR. A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring). 2010;18:35-41.
30. Coetzee GA, Strachan FA, Westhuyzen DR, Hoppe HC, Jeenah MS, Beer FC. Serum amyloid A-containing human high density lipoprotein 3: density, size, and apolipoprotein composition. J Biol Chem. 1986;261:9644-51.
31. Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J, Tietge UJ, Zidek W, van der Giet M. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res. 2012;94:154-62.
32. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH, Stocker R, Säemann MD. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol. 2012;23:934-47.
33. Upragarin N, Landman WJM, Gaastra W, Gruys E. Extrahepatic production of acute phase serum amyloid A. Histol Histopathol. 2005;20:1295-1307.
34. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A. 1994;91:3186-90.
35. Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J Rheumatol. 1999;26:785-90.
36. Sjöholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, Lystig TC, Jennische E, Brandberg J, Torgerson JS, Carlsson B, Carlsson LM. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab. 2005;90:2233-9.
37. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, Snitker S, Horenstein RB, Hull K, Goldberg NH, Goldberg AP, Shuldiner AR, Fried SK, Gong DW. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006;3:e287.
38. Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun. 2000;268:405-8.
39. Niemi K, Baumann MH, Kovanen PT, Eklund KK. Serum amyloid A (SAA) activates human mast cells which leads into degradation of SAA and generation of an amyloidogenic SAA fragment. Biochim Biophys Acta. 2006;1762: 424-430.
40. Koga T, Torigoshi T, Motokawa S, Miyashita T, Maeda Y, Nakamura M, Komori A, Aiba Y, Uemura T, Yatsuhashi H, Ishibashi H, Eguchi K, Migita K. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Lett. 2008;582:579-85.
41. Migita K, Koga T, Torigoshi T, Motokawa S, Maeda Y, Jiuchi Y, Izumi Y, Miyashita T, Nakamura M, Komori A, Ishibashi H. Induction of interleukin-23 p19 by serum amyloid A (SAA) in rheumatoid synoviocytes. Clin Exp Immunol. 2010;162:244-50.
42. Song C, Hsu K, Yamen E, Yan W, Fock J, Witting PK, Geczy CL, Freedman SB. Serum amyloid A induction of cytokines in monocytes/ macrophages and lymphocytes. Atherosclerosis. 2009;207:374-33.
43. Badolato R, Wang JM, Murphy WJ, Lioid AR, Michel DF, Bausserman LL, Kevin DJ, Oppenheim JJ. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med. 1994;180:203-9.
44. Olsson N, Siegbahn A, Nilsson G. Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway. Biochem Biophys Res Commun. 1999;254:143-6.
45. Li L, Kim J, Boussiotis VA. IL-14-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol. 2010;185:4148-5.
46. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009;30:576-87.
47. Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC, Poynter ME. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol. 2011;187:64-73.
48. Nguyen KD, Macaubas C, Nadeau KC, Truong P, Yoon T, Lee T, Park JL, Mellins ED. Serum amyloid A overrides Treg anergy via monocytedependent and Treg-intrinsic, SOCS3-associated pathways. Blood. 2011;117:3793-8.
49. Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, Lucas RM, Nakai J, Smart EJ, Vora DK, Berliner JA. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol. 2003;23:1197-203.
50. Chávez-Sánchez L, Madrid-Miller A, Chávez-Rueda K, Legorreta-Haquet MV, Tesoro-Cruz E, Blanco-Favela F. Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol. 2010;71:737-44.
51. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol. 2010;134:5-24.
52. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol. 2008;181:22-6.
53. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor Blood. 2009;113:429-37.
54. Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, Groshong SD, Zhang Y, Tuder RM, Moller DR. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360-73.
55. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol. 2008;83:1174-80.
56. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006;17:501-19.
57. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G proteincoupled receptor, FPRL1/LXA4R. Blood. 2003;101:1572-81.
58. Lee HY, Kim MK, Park KS, Shin EH, Jo SH, Kim SD, Jo EJ, Lee YN, Lee C, Baek SH, Bae YS. Serum amyloid A induces contrary immune responses via formyl peptide receptorlike 1 in human monocytes. Mol Pharmacol. 2006;70:241-8.
59. Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med. 1999;189:395-402.
60. Lee HY, Kim SD, Shim JW, Lee SY, Lee H, Cho KH, Yun J, Bae YS. Serum amyloid A induces CCL2 production via formyl peptide receptorlike 1-mediated signaling in human monocytes. J Immunol. 2008;181:4332-9.
61. Lee HY, Kim SD, Shim JW, Kim HJ, Yun J, Baek SH, Kim K, Bae YS. A pertussis toxin sensitive G-protein-independent pathway is involved in serum amyloid A-induced formyl peptide receptor 2-mediated CCL2 production. Exp Mol Med. 2010;42:302-9.
62. Lee HY, Kim SD, Shim JW, Yun J, Kim K, Bae YS. Activation of formyl peptide receptor like-1 by serum amyloid A induces CCL2 production in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2009;380:313-7.
63. Badolato R, Johnston JA, Wang JM, McVicar D, Xu LL, Oppenheim JJ, Kelvin DJ. Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol. 1995;155:4004-10.
64. Olsson N, Siegbahn A, Nilsson G. Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway. Biochem Biophys Res Commun. 1999;254:143-6.
65. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268:11811-16.
66. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem. 1994;269:21003-9.
67. Vega MA, Seguí-Real B, García JA, Calés C, Rodríguez F, Vanderkerckhove J, Sandoval IV. Cloning, sequencing, and expression of a cDNA encoding rat LIMP II, a novel 74-kDa lysosomal membrane protein related to the surface adhesion protein CD36. J Biol Chem. 1991;266:16818-24.
68. Calvo D, Vega MA. Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family. J Biol Chem. 1993;268:18929-35.
69. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999;68:523-58.
70. Vishnyakova TG, Bocharov AV, Baranova IN, Chen Z, Remaley AT, Csako G, Eggerman TL, Patterson AP. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem. 2003;278:22771-80.
71. Bocharov AV, Baranova IN, Vishnyakova TG, Remaley AT, Csako G, Thomas F, Patterson AP, Eggerman TL. Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical-containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells. J Biol Chem. 2004;279:36072-82.
72. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, Remaley AT, Csako G, Thomas F, Eggerman TL, Patterson AP. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem. 2005;280:8031-40.
73. Husemann J, Loike JD, Kodama T, Silverstein SC. Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J Neuroimmunol. 2001;114:142-50.
74. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem. 2005;280:2954-61.
75. Baranova IN, Bocharov AV, Vishnyakova TG, Kurlander R, Chen Z, Fu D, Arias IM, Csako G, Patterson AP, Eggerman TL. CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem. 2010;285:8492-506.
76. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99-111.
77. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000;6:643-51.
78. Okamoto H, Katagiri Y, Kiire A, Momohara S, Kamatani N. Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. J Rheumatol. 2008;35:752-6.
79. Kinkley SM, Bagshaw WL, Tam SP, Kisilevsky R. The path of murine serum amyloid A through peritoneal macrophages. Amyloid. 2006;13: 123-34.
80. Hirakura Y, Carreras I, Sipe JD, Kagan BL. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid. 2002;9:13-23.
81. Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid. 2012;19:5-14.
82. Malle E, Münscher G, Müller T, Vermeer H, Ibovnik A. Quantification and mapping of antigenic determinants of serum amyloid A (SAA) protein utilizing sequence-specific immunoglobulins and Eu3+ as a specific probe for time-resolved fluorometric immunoassay. J Immunol Methods. 1995;182:131-44.
83. Malle E, Herz R, Artl A, Ibovnik A, Andreae F, Sattler W. Mapping of antigenic determinants of purified, lipid-free human serum amyloid A proteins. Scand J Immunol. 1998;48:557-61.
84. Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1beta converting enzyme. Ann N Y Acad Sci. 1998;856:1-11.
85. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-65.
86. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210-15.
87. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440:228-32.
88. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-41.
89. Rajamäki K, Lappalainen J, Oörni K, Välimäki E, Matikainen S, Kovanen PT, Eklund KK. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010;5:e11765.
90. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464: 1357-61.
91. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674-7.
92. Muruve DA, Pétrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452:103-7.
93. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol. 2010;22:28-33.
94. Migita K, Koga T, Satomura K, Izumi M, Torigoshi T, Maeda Y, Izumi Y, Jiuchi Y, Miyashita T, Yamasaki S, Aiba Y, Komori A, Nakamura M, Motokawa S, Kawakami A, Nakamura T, Ishibashi H. Serum amyloid A triggers the mosodium urate-mediated mature interleukin-1uuproduction from human synovial fibroblasts. Arthritis Res Ther. 2012;14:R119.
95. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, Hornung V, Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183:787-91.
96. Niemi K, Baumann MH, Kovanen PT, Eklund KK. Serum amyloid A (SAA) activates human mast cells which leads into degradation of SAA and generation of an amyloidogenic SAA fragment. Biochim Biophys Acta. 2006;1762:424-30.
97. Niemi K, Teirilä L, Lappalainen J, Rajamäki K, Baumann MH, Öörni K, Wolff H, Kovanen PT, Matikainen S, Eklund KK. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol. 2011;186:6119-28.
98. Linke RP, Bock V, Valet G, Rothe G. Inhibition of the oxidative burst response of N-formyl peptide-stimulated neutrophils by serum amyloid-A protein. Biochem Biophys Res Commun. 1991;176:1100-5.
99. Renckens R, Roelofs JJ, Knapp S, de Vos AF, Florquin S, van der Poll T. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii pneumonia. J Infect Dis. 2006;193:187-95.
100. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scand J Immunol. 1998;48:410-18.
101. Franco AG, Sandri S, Campa A. High-density lipoprotein prevents SAA-induced production of TNF-TTin THP-1 monocytic cells and peripheral blood mononuclear cells. Mem Inst Oswaldo Cruz. 2011;106:986-92.
102. Kluve-Beckerman B, Hardwick J, Du L, Benson MD, Monia BP, Watt A, Crooke RM, Mullick A. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid. 2011;18:136-46.
103. Tam SP, Ancsin JB, Tan R, Kisilevsky R. Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/-mice. J Lipid Res. 2005;46:2091-101.